Mentions
Extended reach
Total likes
Video views
AI synopsis
Numerous discussions highlight key findings from the study, such as 'Digitoxin reduces death and hospitalization risk in heart failure patients, outperforming placebo' which resonates strongly with healthcare professionals. The engagement level is amplified by phrases like 'fantastic finding' and inquiries about incorporating digitoxin into current therapies, showcasing a proactive approach to the material. The tone reflects a sense of urgency and excitement, indicating a collaborative spirit among users as they discuss possible shifts in treatment paradigms.
The majority of discussions express strong support for the findings, emphasizing the effectiveness of digitoxin compared to placebo.
Users show high curiosity regarding the implications of digitoxin treatment, reflecting on its potential role in clinical practice.
Many posts delve into detailed analysis of the study's methodology and outcomes, creating a rich dialogue around its findings.
Contributors view the publication as having considerable influence on future heart failure treatment protocols, noting its potential to change clinical practices.
Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Editorial: Digitoxin — A Reminder for Digoxin https://t.co/oBEX3T6z8s #Cardiology https://t.co/RsSBar1xpL
New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Apixaban for Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Measurable Residual Disease–Guided Therapy for CLL https://t.co/8e5qUOXjY6
✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine @ChefKarim02 @DrOribaDan @DrJNELLY95 https://t.co/Dlv3aEO5Ap?
ガイドライン推奨薬を使用している低心機能、心不全患者に、 ジゴキシンを加えることで、総死亡、心不全入院が低下傾向となり、複合エンドポイントは有意に低下。1,240例を対象にした無作為化比較試験https://t.co/R4IVpTibZR
Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HFrEF, offering a safe and cost-effective treatment option—even with kidney impairment. @nejm https://t.co/aF3DT0CEbC https://t.co/4jBRQCe2gm
#WNW Gotta talk about DIGIT-HF. In pts with HFrEF (EF ~29%, 67% class III) on GDMT (though <20% were on SGLT2i), adding digitoxin vs placebo lowered risk of all-cause death or 1st HFH (39.5% vs 44.1%) over 36 months. https://t.co/JHRx2mWr1E
This week, John Mandrola MD discusses the effectiveness of digitoxin in heart failure patients and highlights two significant trials from the ESC. The study shows digitoxin reduced death or hospitalization rates but had…
In this video, Dr. Gabryely Dorner presents highlights from ESC 2025, focusing on significant trials such as Digitoxin in patients with heart failure and reduced ejection fraction. The study found digitoxin linked to…
Prof. Dr. John McMurray discusses novel developments in heart failure with reduced ejection fraction (HFREF) treatment, focusing on vericiguat outcomes from the VICTOR study. The findings suggest a reduced risk of…
Digitoxina en pacientes con insuficiencia cardiaca y fracción de eyección reducida https://t.co/PtZqwcpFFa PMID 40879434
Digitoxin reduces death and hospitalization risk in heart failure patients, outperforming placebo in a substantial clinical trial. by Bavendiek U, Großhennig A (...) Bauersachs J et 32 al. in N Engl J Med #MedSky
Digitoxin reduces death and hospitalization risk in heart failure patients, outperforming placebo in a substantial clinical trial. by Bavendiek U, Großhennig A (...) Bauersachs J et 32 al. in N Engl J Med https://t.co/Kscsr0lse6 #MedX #MedResearch
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
El ensayo DIGIT-HF publicado en NEJM demuestra que la digitoxina reduce el riesgo combinado de muerte o reingreso por IC con FEVI reducida. Viejo fármaco, ¿nueva oportunidad? DOI: 10.1056/NEJMoa2415471 https://t.co/K4r9WjgUfA
RT @bmorecardiology: So now what? should we start adding digoxin to our pillars of therapy for HFrEF? https://t.co/xlxge3DkD2 @NEJM @gcfmd…
DIGIT-HF phase 4 trial: In patients with heart failure and reduced ejection fraction, the efficacy of cardiac glycosides when added to contemporary therapies is unclear. Research findings on the safety and efficacy of digitoxin are summarized in a new Quick Take video. nej.md/3IgL4wO
RT @drbennisahmed: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined…
So now what? should we start adding digoxin to our pillars of therapy for HFrEF? https://t.co/xlxge3DkD2 @NEJM @gcfmd @HFSA @drjohnm
RT @yumino_medical: 【DrゆみのWeekly Journal Scan】 ＊収縮機能低下した心不全患者へのジギトキシンの効果 from NEJM＊ https://t.co/CqvspXj0nE DIGIT-HF試験は、標準治療下におけるジギトキシンの有効性…
【DrゆみのWeekly Journal Scan】 ＊収縮機能低下した心不全患者へのジギトキシンの効果 from NEJM＊ https://t.co/CqvspXj0nE DIGIT-HF試験は、標準治療下におけるジギトキシンの有効性を検証した無作為化二重盲検試験。対象は心不全（HFrEF）患者1212例（LVEF≤40%かつNYHA
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who https://t.co/wQwqtM2GEK
2 min cardiology（臨床、担当：千葉直貴） Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction U Bavendiek et al. NEJM Aug 29, 2025 https://t.co/dgZRZf0vrv →
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @DrPascalMeier: In HFrEF patients on guideline-directed therapy, digitoxin reduced death or HF hospitalization vs placebo. DIGIT-HF (Pha…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
In HFrEF patients on guideline-directed therapy, digitoxin reduced death or HF hospitalization vs placebo. DIGIT-HF (Phase 4, n=1212) now published in @NEJM Another old drug showing new value.
In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results and Research Summary: nej.md/3HQHLfj
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
RT @rkalyes1: ✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with…
✍️ Digitoxin (not digoxin this time) still has a roll in HFrEF but you must keep that dose low! ✍️Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine @ChefKarim02 @DrOribaDan @DrJNELLY95 https://t.co/Dlv3aEO5Ap?
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Editorial: Digitoxin — A Reminder for Digoxin https://t.co/oBEX3T6z8s #Cardiology https://t.co/RsSBar1xpL
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction @NEJM https://t.co/3CJBZii1L9 treatment with digitoxin led to a
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
Déjà vu ! Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/vv61muTISN
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/3BhbmmLnP2
RT @Carcos2: "El tratamiento con digitoxina⬇️el riesgo de muerte por cualquier causa o ingreso hospitalario por agravamiento de la IC vs.…
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Apixaban for Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Measurable Residual Disease–Guided Therapy for CLL https://t.co/8e5qUOXjY6
RT @sgoto4: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/JqLgVDV0W…
RT @sgoto4: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/JqLgVDV0W…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/JP4v7OArYC
"El tratamiento con digitoxina⬇️el riesgo de muerte por cualquier causa o ingreso hospitalario por agravamiento de la IC vs. placebo en pacientes con IC y⬇️FE que recibieron tto médico según las guías" No ganamos para sorpresas. Digitoxina, no digoxina https://t.co/OFbyhoynz9
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/JqLgVDV0WN 歴史的ジギタリスにはHFrEFの予後改善効果があるね！
RT @Susumu_Manabe: ガイドライン推奨薬を使用している低心機能、心不全患者に、 ジゴキシンを加えることで、総死亡、心不全入院が低下傾向となり、複合エンドポイントは有意に低下。1,240例を対象にした無作為化比較試験https://t.co/R4IVpTibZR
ガイドライン推奨薬を使用している低心機能、心不全患者に、 ジゴキシンを加えることで、総死亡、心不全入院が低下傾向となり、複合エンドポイントは有意に低下。1,240例を対象にした無作為化比較試験https://t.co/R4IVpTibZR
RT @drbennisahmed: DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction #esccongress #WCCardio #CardioED #MedE…
標準治療が行われているHFrEF患者に対してジギトキシンは全死亡、心不全による入院の複合アウトカムが少なかった(HR0.82).DIGIT-HF trial. N Engl J Med. PMID: 40879493.https://t.co/oDDRgZdiJp
RT @drbennisahmed: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined…
RT @accpcardprn: #WNW Gotta talk about DIGIT-HF. In pts with HFrEF (EF ~29%, 67% class III) on GDMT (though <20% were on SGLT2i), adding di…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who https://t.co/2krqDmmRis
RT @Derek_Leong_RPh: DIGIT-HF trial: In Pts with HFrEF, NYHA II-IV, on contemporary GDMT, digitoxin (dosed to target level 10.5-23.6 nmol/L…
DIGIT-HF trial: In Pts with HFrEF, NYHA II-IV, on contemporary GDMT, digitoxin (dosed to target level 10.5-23.6 nmol/L) ⬇️ all-cause mortality/HF hospitalization vs. placebo (ARR 4.6% at 36 months). https://t.co/0A9RGayz7w https://t.co/zYVsFp5NY0
RT @ChuckGartland1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/S…
RT @pinacol: 【RCT】LVEF40%以下でNYHA分類IIIまたはIV、もしくはLVEF30%以下でNYHA分類IIの慢性心不全患者へのジギトキシンの投与は、プラセボの投与と比較して、全原因死亡、心不全悪化による入院の複合転帰を減少させた。 #ペ読 https:/…
RT @accpcardprn: #WNW Gotta talk about DIGIT-HF. In pts with HFrEF (EF ~29%, 67% class III) on GDMT (though <20% were on SGLT2i), adding di…
RT @accpcardprn: #WNW Gotta talk about DIGIT-HF. In pts with HFrEF (EF ~29%, 67% class III) on GDMT (though <20% were on SGLT2i), adding di…
#WNW Gotta talk about DIGIT-HF. In pts with HFrEF (EF ~29%, 67% class III) on GDMT (though <20% were on SGLT2i), adding digitoxin vs placebo lowered risk of all-cause death or 1st HFH (39.5% vs 44.1%) over 36 months. https://t.co/JHRx2mWr1E
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/S4gA23ASEU DIGITOXIN is not digoxin. I know because Dr. Eby made us memorize the similarities and differences in Pharmacognosy class Temple Pharm.
RT @AnilMakam: 3| DIGIT-HF Is GDMT for HF coming full circle? In a double-blind multicenter trial of advanced HFrEF, digitoxin—a safer di…
3| DIGIT-HF Is GDMT for HF coming full circle? In a double-blind multicenter trial of advanced HFrEF, digitoxin—a safer digoxin analog not available in the US—reduced mortality & hospitalizations A Dutch trial of digoxin is underway! https://t.co/n4pHqKdy2S
RT @drbennisahmed: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined…
【RCT】LVEF40%以下でNYHA分類IIIまたはIV、もしくはLVEF30%以下でNYHA分類IIの慢性心不全患者へのジギトキシンの投与は、プラセボの投与と比較して、全原因死亡、心不全悪化による入院の複合転帰を減少させた。 #ペ読 https://t.co/U1bLKLAod9
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @mzkhalil: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #ESCCongress Okay for Digitoxin in HFrEF… bu…
RT @drbennisahmed: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined…
RT @drbennisahmed: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who https://t.co/36ere8hcsl
Y si quieres leer el ensayo completo, este es el link: https://t.co/MWwqJ5wlkA ➡️3-year follow-up: primary outcome event of all-cause death or first hospitalization for #heartfailure occurred in 39.5% of patients in the #digitoxin group vs 44.1% placebo. RAR=4,6% (NNT=22) #HFrEF https://t.co/Wa8KTTBMDL
RT @ffaviles: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/h553faz…
RT @BITNavarra: Digitoxina en pacientes con insuficiencia cardiaca y fracción de eyección reducida
RT @drraviele: https://t.co/i7IcQao8Oo
https://t.co/i7IcQao8Oo
RT @BITNavarra: Digitoxina en pacientes con insuficiencia cardiaca y fracción de eyección reducida
Digitoxina en pacientes con insuficiencia cardiaca y fracción de eyección reducida
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/3PeYXCNwDZ
Dig again for the win. In pts with HF and ⬇️ E.F, digitoxin led to ⬇️ ☠️ from any cause or hospitalization for worsening HF compared to placebo. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/PPZcx2JCSB
HFrEF患者1240人を対象とした国際RCT（DIGIT-HF）では，digitoxinはプラセボより総死亡または心不全増悪入院を減らした（39.5％対44.1％，HR 0.82，0.69～0.98）．総死亡（HR 0.86）や入院（HR 0.85）は単独では有意に減らなかった． https://t.co/k9JX8MsCxL
https://t.co/XgHBo21Jqr ❤️ #digoxin
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
Can we get Digitoxin in the USA? Not sure I would use digoxin from these results.. although compelling.. https://t.co/xlxge3DkD2 #DIGITHF @NEJM @gcfmd @HFSA @drjohnm
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/L6tXYLtZgd
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @antithrombosis: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/a…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/aDVQVZMA3W ジギタリス、意外によかったね！驚きでした！
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
Catching up on the ESC (I was away... more later) and excited to read the Digit-HF study and @drjohnm 's digest of it. Cardiac glycosides do have a role in HFrEF, with digitoxin additive to contemporary HF management in reducing death/hospitalisation https://t.co/bw3HBPN3EN
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
今日実習生に教えたこと
A fantastic finding #DIGIT_HF trial @NEJM adding #Digitoxin to #GDMT for #HFrEF reduces all cause mortality + HFHospitalisation @BSHeartFailure @BritishCardioSo @SheffieldHosp @sheffielduni #CardioTwitter @TheresaMcDonag3 https://t.co/eeJFpoeQzA
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @mzkhalil: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #ESCCongress Okay for Digitoxin in HFrEF… bu…
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @mzkhalil: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #ESCCongress Okay for Digitoxin in HFrEF… bu…
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @DrDamluji: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction: @NEJM
RT @FormigaFrancesc: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/…
RT @mzkhalil: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #ESCCongress Okay for Digitoxin in HFrEF… bu…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM #ESCCongress Okay for Digitoxin in HFrEF… but wait  The only available ARNI is sacubitril/valsartan (ARNI+ARB) yet they manage to recruit 40% ARNI & 18% ARB..!! Analyze
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/56reWx7nhc
HFpEFへのジゴキシン、composite（死亡＋初回心不全入院）改善。サブグループはEF＜30や血圧低下に特に有効。KMが3ヶ月で重なるのが気になります https://t.co/eyYrWS0bCP ランドマークのDIG試験は二重盲検してなく、そこから数十年あいていた。予定より少なく終了しており、現在走ってるRCTに期待です https://t.co/VUhVG1mAqJ
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine. Revisiting a classic. Results: very surprising! https://t.co/J8r1tH7OOz
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
DIGIT-HF trial An old drug might be added to GDMT?! The study drug was digitoxin—not digoxin. They’re different molecular profiles. When HF hospitalisations were analysed alone, there was no improvement. Waiting for Digoxin trial “DECISION trial” https://t.co/9jZjwOqS2H
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @FormigaFrancesc: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @NEJM: Original Article: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF phase 4 trial) https://t.co/8m…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
Hot Line 1 – DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction European Society of Cardiology youtu.be/dd6dF81KyhE?...
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
RT @medical_xpress: Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HF…
Digitoxin, derived from red foxglove, significantly reduces mortality and hospitalizations in patients with advanced HFrEF, offering a safe and cost-effective treatment option—even with kidney impairment. @nejm https://t.co/aF3DT0CEbC https://t.co/4jBRQCe2gm
"Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction." Présenté ce jour à l' #ESCCongress et publié dans le @nejm.org. #MedSky #CardioSky www.nejm.org/doi/full/10....
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction (DIGIT-HF Phase 4 trial) nej.md/3HQHLfj Multidomain Rehabilitation for Older Patients with Myocardial Infarction (PIpELINe trial) nej.md/4fRsuYh